Harpoon therapeutics inc
WebOct 26, 2024 · SOUTH SAN FRANCISCO, Calif., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today... WebApr 7, 2024 · Harpoon Therapeutics Inc. (NASDAQ:HARP) price on Thursday, April 06, fall -5.07% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.65. A look at the stock’s price movement, the close in the last trading session was $0.68, moving within a range at $0.6306 and $0.697.
Harpoon therapeutics inc
Did you know?
WebHARP - Harpoon Therapeutics, Inc. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. × publish chart save to portfolio create alert compare perf. Candle - advanced Daily Draw Fullscreen Settings HARP - Stock Price Chart HARP [NASD] Harpoon Therapeutics, Inc. WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology …
WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that Julie Eastland, President and Chief Executive Officer, and Luke Walker, M.D., Chief Medical Officer, will … WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that Julie Eastland, President and Chief Executive Officer, and Luke Walker, M.D., Chief Medical Officer, will participate in a …
WebMar 27, 2024 · SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported ... WebMar 27, 2024 · Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases.
WebMar 27, 2024 · Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the ...
WebApr 10, 2024 · Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body's immune … temporada 2 merlinaWebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology … temporada 2 merlina 2023WebPublications from Harpoon Therapeutics, an immuno-oncology company using a proprietary technology platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases. Publications. HPN328. ASCO 2024 (pdf) AACR 2024 (pdf) temporada 2 outer banksWebMar 27, 2024 · SOUTH SAN FRANCISCO, Calif., March 27, 2024 —Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update. “Harpoon is well … temporada 2 obi wan kenobiWebMar 27, 2024 · Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. temporada 2 owari no seraphWebApr 10, 2024 · Harpoon Therapeutics Seeks $86 Million U.S. IPO Donovan Jones Thu, Jan. 03, 2024 Share your Analysis on HARP Submit an article now News Harpoon Therapeutics GAAP EPS of -$0.55 misses by... temporada 2 pantanalWebApr 1, 2024 · Currently, the most bullish analyst values Harpoon Therapeutics at US$16.00 per share, while the most bearish prices it at US$1.50. With such a wide range in price targets, the analysts are... temporada 2 ranking of kings